97 related articles for article (PubMed ID: 27918994)
1. Importance of 5/6-aryl substitution on the pharmacological profile of 4'-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid derived PPARγ agonists.
Obermoser V; Mauersberger R; Schuster D; Czifersky M; Lipova M; Siegl M; Kintscher U; Gust R
Eur J Med Chem; 2017 Jan; 126():590-603. PubMed ID: 27918994
[TBL] [Abstract][Full Text] [Related]
2. New telmisartan-derived PPARγ agonists: Impact of the 3D-binding mode on the pharmacological profile.
Obermoser V; Urban ME; Murgueitio MS; Wolber G; Kintscher U; Gust R
Eur J Med Chem; 2016 Nov; 124():138-152. PubMed ID: 27569195
[TBL] [Abstract][Full Text] [Related]
3. Characterization of telmisartan-derived PPARγ agonists: importance of moiety shift from position 6 to 5 on potency, efficacy and cofactor recruitment.
Herbst L; Goebel M; Bandholtz S; Gust R; Kintscher U
ChemMedChem; 2012 Nov; 7(11):1935-42. PubMed ID: 24155042
[TBL] [Abstract][Full Text] [Related]
4. Characterization of new PPARgamma agonists: benzimidazole derivatives-importance of positions 5 and 6, and computational studies on the binding mode.
Goebel M; Wolber G; Markt P; Staels B; Unger T; Kintscher U; Gust R
Bioorg Med Chem; 2010 Aug; 18(16):5885-95. PubMed ID: 20656494
[TBL] [Abstract][Full Text] [Related]
5. Characterization of new PPARgamma agonists: analysis of telmisartan's structural components.
Goebel M; Clemenz M; Staels B; Unger T; Kintscher U; Gust R
ChemMedChem; 2009 Mar; 4(3):445-56. PubMed ID: 19197922
[TBL] [Abstract][Full Text] [Related]
6. Characterization of new PPARgamma agonists: benzimidazole derivatives - the importance of position 2.
Goebel M; Staels B; Unger T; Kintscher U; Gust R
ChemMedChem; 2009 Jul; 4(7):1136-42. PubMed ID: 19504532
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for telmisartan-mediated partial activation of PPAR gamma.
Amano Y; Yamaguchi T; Ohno K; Niimi T; Orita M; Sakashita H; Takeuchi M
Hypertens Res; 2012 Jul; 35(7):715-9. PubMed ID: 22357520
[TBL] [Abstract][Full Text] [Related]
8. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
[TBL] [Abstract][Full Text] [Related]
9. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
Liu W; Lau F; Liu K; Wood HB; Zhou G; Chen Y; Li Y; Akiyama TE; Castriota G; Einstein M; Wang C; McCann ME; Doebber TW; Wu M; Chang CH; McNamara L; McKeever B; Mosley RT; Berger JP; Meinke PT
J Med Chem; 2011 Dec; 54(24):8541-54. PubMed ID: 22070604
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Characterization of Telmisartan-Derived Cell Death Modulators to Circumvent Imatinib Resistance in Chronic Myeloid Leukemia.
Schoepf AM; Salcher S; Hohn V; Veider F; Obexer P; Gust R
ChemMedChem; 2020 Jun; 15(12):1067-1077. PubMed ID: 32298535
[TBL] [Abstract][Full Text] [Related]
11. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro.
Burgermeister E; Schnoebelen A; Flament A; Benz J; Stihle M; Gsell B; Rufer A; Ruf A; Kuhn B; Märki HP; Mizrahi J; Sebokova E; Niesor E; Meyer M
Mol Endocrinol; 2006 Apr; 20(4):809-30. PubMed ID: 16373399
[TBL] [Abstract][Full Text] [Related]
12. A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones.
Tagami T; Yamamoto H; Moriyama K; Sawai K; Usui T; Shimatsu A; Naruse M
Endocrinology; 2009 Feb; 150(2):862-70. PubMed ID: 19147680
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
Montanari R; Saccoccia F; Scotti E; Crestani M; Godio C; Gilardi F; Loiodice F; Fracchiolla G; Laghezza A; Tortorella P; Lavecchia A; Novellino E; Mazza F; Aschi M; Pochetti G
J Med Chem; 2008 Dec; 51(24):7768-76. PubMed ID: 19053776
[TBL] [Abstract][Full Text] [Related]
15. Different structures of the two peroxisome proliferator-activated receptor gamma (PPARγ) ligand-binding domains in homodimeric complex with partial agonist, but not full agonist.
Ohashi M; Oyama T; Miyachi H
Bioorg Med Chem Lett; 2015 Jul; 25(13):2639-44. PubMed ID: 25987371
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma (PPARγ) has multiple binding points that accommodate ligands in various conformations: Structurally similar PPARγ partial agonists bind to PPARγ LBD in different conformations.
Ohashi M; Gamo K; Oyama T; Miyachi H
Bioorg Med Chem Lett; 2015 Jul; 25(14):2758-62. PubMed ID: 26025876
[TBL] [Abstract][Full Text] [Related]
17. Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase.
Yuen CY; Wong WT; Tian XY; Wong SL; Lau CW; Yu J; Tomlinson B; Yao X; Huang Y
Cardiovasc Res; 2011 Apr; 90(1):122-9. PubMed ID: 21156825
[TBL] [Abstract][Full Text] [Related]
18. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator.
Kurtz TW
Acta Diabetol; 2005 Apr; 42 Suppl 1():S9-16. PubMed ID: 15868121
[TBL] [Abstract][Full Text] [Related]
19. Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds.
Nevin DK; Peters MB; Carta G; Fayne D; Lloyd DG
J Med Chem; 2012 Jun; 55(11):4978-89. PubMed ID: 22582973
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
Casimiro-Garcia A; Heemstra RJ; Bigge CF; Chen J; Ciske FA; Davis JA; Ellis T; Esmaeil N; Flynn D; Han S; Jalaie M; Ohren JF; Powell NA
Bioorg Med Chem Lett; 2013 Feb; 23(3):767-72. PubMed ID: 23265881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
